© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
September 03, 2008
Patients with type 2 diabetes mellitus have decreased platelet inhibition and decreased responsiveness to standard doses of clopidogrel compared with patients without diabetes. In this pilot study, we showed that increasing the maintenance dose of clopidogrel to 150 mg leads to enhanced platelet inhibition compared with the standard dose of 75 mg in patients with type 2 diabetes with suboptimal responsiveness. The clinical implications of these findings are unknown, however, and need to be evaluated in large-scale clinical trials.
Eyes with nAMD Treated with Ranibizumab Maintained Visual Acuity at SRF Resolution
Dietary Eliminations May Not Significantly Benefit Pediatric Eczema
Antibiotics to Treat Upper Respiratory Infections Increase Risk of C Difficile Infections